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Tregs control the development of symptomatic
West Nile virus infection in humans and mice
Marion C. Lanteri,1 Katie M. O’Brien,2 Whitney E. Purtha,2 Mark J. Cameron,3
Jennifer M. Lund,4 Rachel E. Owen,1,5 John W. Heitman,1 Brian Custer,1 Dale F. Hirschkorn,1
Leslie H. Tobler,1 Nancy Kiely,6 Harry E. Prince,7 Lishomwa C. Ndhlovu,5 Douglas F. Nixon,5
Hany T. Kamel,6 David J. Kelvin,3,8 Michael P. Busch,1,9 Alexander Y. Rudensky,10
Michael S. Diamond,2 and Philip J. Norris1,5,9
1Blood Systems Research Institute, San Francisco, California, USA. 2Department of Medicine, Department of Molecular Microbiology, and
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. 3University Health Network and
Department of Immunology, University of Toronto, Toronto, Ontario, Canada. 4Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer
Research Center, Seattle, Washington, USA. 5Department of Medicine, UCSF, San Francisco, California, USA. 6Blood Systems Inc., Scottsdale, Arizona, USA.
7Focus Diagnostics, Cypress, California, USA. 8Division of Immunology, International Institute of Infection and Immunity, Shantou University Medical College,
Shantou, Guangdong, People’s Republic of China. 9Department of Laboratory Medicine, UCSF, San Francisco, California, USA.
10HHMI and Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

West Nile virus (WNV) causes asymptomatic infection in most humans, but for undefined reasons, approximately 20% of immunocompetent individuals develop West Nile fever, a potentially debilitating febrile illness,
and approximately 1% develop neuroinvasive disease syndromes. Notably, since its emergence in 1999, WNV
has become the leading cause of epidemic viral encephalitis in North America. We hypothesized that CD4+
Tregs might be differentially regulated in subjects with symptomatic compared with those with asymptomatic
WNV infection. Here, we show that in 32 blood donors with acute WNV infection, Tregs expanded significantly in the 3 months after index (RNA+) donations in all subjects. Symptomatic donors exhibited lower Treg
frequencies from 2 weeks through 1 year after index donation yet did not show differences in systemic T cell or
generalized inflammatory responses. In parallel prospective experimental studies, symptomatic WNV-infected
mice also developed lower Treg frequencies compared with asymptomatic mice at 2 weeks after infection.
Moreover, Treg-deficient mice developed lethal WNV infection at a higher rate than controls. Together, these
results suggest that higher levels of peripheral Tregs after infection protect against severe WNV disease in
immunocompetent animals and humans.
Introduction
West Nile virus (WNV), an encephalitic positive polarity RNA virus
of the Flaviviridae family, was first isolated in 1937 in the West Nile
district of Uganda from the blood of a febrile woman (1). It entered
North America in 1999 and spread rapidly across the United States
and Canada, and nearly 29,000 symptomatic infections including
fever, meningitis, and/or encephalitis and over 1100 deaths have
been reported by the CDC (2). Based on blood supply screening
and seroprevalence testing, recent estimates suggest that approximately 2 million people have been infected during the epidemic,
most with clinically unapparent cases (3).
Considerable progress in understanding the kinetics and mechanisms of viral dissemination and pathogenesis has been made
studying WNV infection in rodent models (4). Innate immune
responses, interferon secretion (5, 6), complement activation (7),
and cellular innate immunity (8, 9) function to limit the spread
and replication of WNV. Studies on the humoral response have
established that neutralizing antibodies (10) are also protective
(11). T cell responses also contribute to viral clearance (12, 13),
as release of proinflammatory cytokines and antigen-restricted
CTL responses are seen in mice (14) and humans (15), with perforin and granzymes required for WNV clearance from the CNS of
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infected mice (16, 17). While an intact immune response is clearly
key to control of WNV infection (18), an overexuberant immune
response may also contribute to disease (19, 20).
CD4+ Tregs are able to suppress effector T cells to prevent or
control reactivity to self antigens (21) and pathogens (22), to
blunt inflammation (23), and to maintain antigen-specific T cell
homeostasis (24). Multiple Treg populations have been reported (25), with naturally occurring Tregs the most widely studied
and best characterized (26). Natural Tregs constitutively express
molecules such as CD25 (IL-2 receptor α-chain) (27), cytotoxic T
lymphocyte–associated antigen 4 (CTLA-4 or CD152) (28), and
glucocorticoid-induced TNF receptor (GITR) (29), also expressed
by nonregulatory T cells after activation. More specifically, Tregs
express the forkhead/winged helix transcription factor gene forkhead box P3 (Foxp3), described as a key control gene in their development and function (30). More recent studies demonstrate that
Tregs also express low levels of CD127 (31, 32). While no single
marker uniquely identifies Treg populations, panels of markers
allow identification of CD4+ T cells with suppressive activity.
In the present study, we explored the hypothesis that Treg levels
in individuals with WNV infection associate with disease outcome.
Serial samples were collected from a cohort of WNV+ blood donors,
identified through routine screening for WNV RNA in blood donations. The presence or absence of WNV fever was determined using
questionnaires, and effector immune responses and Treg levels were
followed for 1 year after infection. Donors who developed symptomatic WNV infection possessed lower Treg levels at each point mea-
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Table 1
Subject characteristics
Donor

Age

Sex

Residence
state

Before
donation

Index donation

After donation

Peak
symptom
numberB

Symptom
number

IgM

IgG

Symptom
number

After
index (d)A

IgM

IgG

Symptom
number

Asymptomatic ≤3
9860C
650
1150
1650
1950
2350
2450
2950
3550
350
750
950
550
2550
1250
250
1450
3050

73
44
50
43
24
52
73
25
57
60
46
55
45
39
75
36
38
59

F
F
F
F
M
M
F
F
F
F
F
F
F
F
F
F
F
F

Arizona
New Mexico
New Mexico
North Dakota
New Mexico
Arizona
Arizona
Mississippi
Arkansas
California
Texas
Nevada
South Dakota
Arizona
South Dakota
South Dakota
Texas
Mississippi

2
0
0
0
0
0
0
0
0
0
1
0
0
3
0
2
0
2

–
–
–
–
–
–
–
–
–
–
–
–
–
–
+
+
+
+

–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
+
+

0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0

7
10
12
20
14
19
18
28
17
12
8
10
13
12
20
12
15
13

–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

–
+
+
+
+
+
+
+
+
–
–
+
+
+
+
+
+
+

0
ND
0
0
0
0
0
ND
0
1
0
2
3
0
0
1
1
0

2
0
0
0
0
0
0
0
0
1
1
2
3
3
0
2
1
2

F
M
M
M
F
F
F
M
F
M
F
F
F
M

South Dakota
Arizona
Arizona
Mississippi
Mississippi
Minnesota
Arizona
North Dakota
South Dakota
Texas
South Dakota
North Dakota
California
Minnesota

0
0
0
3
1
5
0
4
7
3
9
4
5
5

–
–
–
–
–
+
–
–
–
–
–
–
–
+

–
–
–
–
+
–
–
–
–
–
–
–
–
+

0
1
2
0
0
0
4
4
0
2
3
5
1
2

10
15
12
15
12
15
22
10
25
43
14
12
15
15

+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
–
+
+
+
+
+
+
+
+
+
+
+

5
5
5
5
4
2
5
2
4
8
4
8
12
5

5
5
5
5
4
5
5
4
7
8
9
8
12
5

Symptomatic ≥4
450
2650
1850
150
2250D
1750
2850
1050
3150
3350
1350
2050
850
1550

47
46
49
51
39
50
31
54
25
38
72
52
26
47

ADays

between index blood donation and the first study visit, the first sample from which PBMCs and plasma could be isolated. BHighest number of symptoms reported on either questionnaire. CDonor 9860 seroconverted at day 12 after index donation. DDonor 2250 showed negative WNV plaque-reduction
neutralization test at day 10, with titers rising to 1:5120 at day 16. ND, not done.

sured after infection, even when Treg levels had returned to baseline
1 year after infection. Parallel prospective studies in a mouse model
of WNV infection confirmed the observations in humans.
Results
Study cohort characteristics. From over 800,000 United Blood Services
donations screened for WNV in 2005, plasma from 45 donors tested positive for WNV RNA. Thirty-two of these WNV+ donors were
entered in this study and completed 2 symptom questionnaires
administered at enrollment and 2 weeks after index donation.
Validation of the questionnaires using donors with acute WNV
or an initial false-positive WNV test revealed that of 12 possible
symptoms (see Methods), the presence of 4 or more symptoms
was associated with true WNV infection (odds ratio 3.28; 95% CI,

1.71–6.28) (33). Given that up to 3 symptoms were found in noninfected donors, this cutoff was used to designate WNV+ donors as
asymptomatic (<4 symptoms) or symptomatic (≥4 symptoms). The
most frequent symptom reported by the asymptomatic population
was new skin rash (17% of asymptomatic), while the symptomatic
populations most frequently reported body aches, headache, and
weakness (88%, 76%, and 65%, respectively for symptomatic), then
fever or eye pain (53% each). Most of the donors (81%) were enrolled
while still in a very early phase of infection (WNV RNA+, IgM–IgG–;
Table 1), and all seroconverted within 43 days of donation.
Identification of CD4+CD25hi Tregs. Tregs express several markers, such as CD25 (27), Foxp3 (30), GITR (29), and CTLA-4 (28),
yet lack expression of CD127 (34) and are commonly defined as
CD4+CD25hiFoxp3+ T cells. To validate our Treg-gating analy-
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Figure 1
Identification of Tregs. PBMCs were stained ex vivo for CD3, CD4, CD25, Foxp3, CD152, and CD127. Lymphocytes were gated and dead cells
excluded. (A) The Foxp3 cell gate was set to exclude Foxp3– and CD25– events within CD3+CD4+ cell populations. CD152+CD127– events were
measured in CD25+Foxp3+lo (52%) and CD25+Foxp3+hi cells (95%) and in (B) CD25neg (4%), CD25int (5%), and CD25hi cells (63%). Levels of
CD152, CD127, and Foxp3 staining were measured in CD25neg, CD25int, and CD25hi populations using selected gates. (C) CD25hi cells were
68.9% CD152+, 14.3% CD127–, and 80.7% Foxp3+, compared with respective values of 13.2%, 89.9%, and 3.7% for CD25int cells and 8.6%,
79.8%, and 0.6% for CD25neg cells. Results are from 1 representative of 3 normal human controls tested in 4 independent experiments. (D)
Agarose gel with DNA stained with ethidium bromide. Expression of Foxp3 in CD4+CD25+ T cells compared with PBMCs or CD4+CD25– T cells,
normalized for RNA input using β-actin primers (gel representative of 3 different experiments).

sis, normal donor PBMCs were stained for CD3, CD4, CD25,
CD152, CD127, and Foxp3. Live CD3+CD4+ cells were gated for
analysis, with further gating on Foxp3+CD25+ cells. The gated
CD3+CD4+CD25+Foxp3+ cells were primarily CD152 +CD127–
(Figure 1A). As described by others (31), the CD4+ T cells with the
highest expression of CD25 constitutively expressed intracellular
CTLA-4/CD152 and had low levels of CD127 (Figure 1B). In addi3268

tion, CD25hiCD152+CD127– T cells expressed more Foxp3 than
CD25int or CD25lo populations (Foxp3 mean linear fluorescence
intensity = 518, 345, and 282, respectively; Figure 1C). Conversely,
CD4+CD25hiFoxp3+ T cells fell in the CD127–/CD152+ gate. Tregs
were defined as CD4+CD25hiCD152+CD127–.
Phenotypic study of CD4+CD25hiCD152+CD127– Tregs. CD4+CD25+
and CD4+CD25neg/int T cell populations were purified from PBMCs
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Figure 2
Suppressive capacity of Tregs. (A) Comparison of CD25, CD127, and CD152 expression within CD4+ T cell fractions before magnetic bead
separation (left panels) and after separation within Treg-depleted PBMCs (middle panels) and purified Tregs (right panels) from a normal human
control. (B) CD25-depleted CD4+ T cells from a normal control and a representative WNV+ donor were stained with CFSE (CFSE+, right peak
and middle population). After 4 days of incubation alone, with anti-CD3/CD28, or with anti-CD3/CD28 plus Tregs (CFSE–, left peak), proliferation
was analyzed after staining for CD4 and propidium iodide. Tregs were not stained and appear at the far left of the plot. Dot plots are shown for
1 representative WNV– donor. (C) Bar diagrams are representative of 3 WNV– and 3 WNV+ donors, with samples collected 30 days after index
donation for the WNV+ donors. Treg suppression of anti-CD3/CD28–induced proliferation at 4 days is shown at varied effector to Treg ratios,
averaging experiments from 3 WNV– and WNV+ donors (error bars represent SEM).

by magnetic bead separation. Flow cytometric analysis demonstrated enrichment of CD152+CD127–Foxp3+ T cells in the CD4+CD25+
population compared with the CD25-depleted population (data
not shown). The enrichment in Foxp3-expressing cells was also
shown at the transcriptional level by RT-PCR (Figure 1D). To test
the functional activity of the cells we identified as Tregs, the isolated
CD4+CD25+ T cell fraction enriched in CD25hiCD152+CD127– cells
(Figure 2A) was added back to CD25–CD4+ T cells stained with
CFSE, and cultures were incubated for 4 days in the presence of stimulatory anti-CD3/CD28 antibodies. As anticipated, CD4+CD25hi
cells inhibited the proliferation of CD4+CD25– T cells (Figure 2B).
Tregs from WNV-infected and healthy donors were equally effective at inhibiting proliferation at ratios of responder/Tregs of

1:1, 2:1, or 4:1 (Figure 2C). These experiments confirmed that the
CD4+CD25hiCD152+CD127– gate identified functional Tregs.
Treg frequency increases following acute WNV infection. Mean
CD4+CD25+CD127lo or Treg frequencies in the 32 WNV+ donors
were compared with those of 17 normal controls. Treg frequencies
in WNV+ donors increased from 1.47% at 18 days after index donation to 2.62% at 90 days after index donation, with a significant
increase compared with WNV– donors from 30 days (P < 0.01) to
90 days after index donation (P < 0.0001) (Figure 3). By 1 year,
postindex donation Treg frequencies had returned to a presumed
baseline, which was indistinguishable from that of normal donors
(1.33% and 1.24%, respectively, P = 0.52). These data demonstrate
that Tregs expand continuously in humans during and after WNV
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Figure 3
Increased Treg frequencies after WNV infection. Live CD3+CD4+ lymphocytes were gated on CD25+CD127loCD152+ (shaded area, Tregs).
Evolution of Treg frequencies expressed as percentage of CD3+ T cells in 17 healthy WNV– donors and in 32 WNV+ donors at 5 time points after
index donation. Twenty-one samples were available for the greater than 18 days time point, 30 at 30 days after index donation, 20 at 60 and 90
days after index donation, 17 at 365 days after index donation. **P < 0.01; ***P < 0.0001.

for 2 to 3 months after index donation and contract back to a baseline level by 1 year after index donation.
Symptomatic subjects exhibit lower Treg levels than asymptomatic subjects.
We hypothesized that higher Treg frequency might correlate with
less symptomatic WNV infection. While Tregs might be expected
to impede clearance of a potentially chronic infection (35, 36),
their presence also could ameliorate symptoms caused by “collateral damage” of the immune response to an acute viral infection.
Indeed, symptomatic donors had lower frequencies of Tregs than
asymptomatic donors from the earliest time point tested through
resolution of infection (P = 0.02 at <18 days, P = 0.04 at 60 days,
P = 0.06 at 365 days after index donation; Figure 4). Analysis using
generalized estimating equations showed that Treg frequency was
41% lower (95% CI, 13%–60%, P = 0.008) in symptomatic compared
with asymptomatic donors across all time periods. Although Treg
frequency has been reported to increase with age (37) and nonneuroinvasive yet symptomatic WNV fever is more common in
younger subjects (38), we observed no significant difference in the
mean age of asymptomatic and symptomatic donors in our cohort
(asymptomatic = 48.5 and symptomatic = 44.8 years, P = 0.44 for
asymptomatic vs. symptomatic; Figure 5A) and only a weak correlation between Treg frequency and age (r2 = 0.19; Figure 5B).
Lower Treg levels are observed in symptomatic versus asymptomatic
WNV-infected mice. Because preinfection samples were not available
for the human studies, it was impossible to evaluate whether the
difference in Treg frequencies between symptomatic and asymptomatic subjects predated WNV infection or whether these differences developed during the first 2 weeks of infection, prior to the
first Treg measurement. To test this hypothesis, we compared Treg
values with WNV disease outcome phenotypes after infection of
C57BL/6 mice. Mice were infected with a low inoculum (1 PFU) of a
virulent North American WNV strain and followed daily for changes
in body weight, appearance, and activity. A group of 20 mice were
euthanized at day 8 after infection, and levels of infectious WNV
were quantified in the brain and spinal cord. Symptomatic mice
(hunchback posture and fur ruffling) showed a concordance among
clinical appearance (Figure 6A), weight loss, viral titer in the spinal
cord and the brain at day 8 (Figure 6, B–D), and mortality. Another
group of 40 mice was followed prospectively, with blood collected
3270

preinfection and at days 14 and 28 after infection. At 28 days after
infection, the survival rate was 43% (Figure 6E), consistent with
prior studies (39). Tregs were defined as CD4+CD25+CD152+Foxp3+
cells (Figure 6F). Unlike in humans, Treg levels decreased in symptomatic mice that succumbed to WNV infection (Figure 6G).
While the mice that died within 28 days of infection had slightly
lower preinfection Treg frequencies than those that survived,
the difference was not statistically significant (died = 4.10%,
survived = 5.43% at day 7, P = 0.3). Lower levels of Tregs were
observed in blood at day 14 after infection in mice that ultimately
succumbed (died = 2.93%, survived = 5.80% at day 14, P = 0.004;
Figure 6G). The finding of lower Treg levels at day 14 in mice that
ultimately succumbed to infection was analogous to the findings of
lower Treg levels in symptomatic humans. Interestingly, an inverse
correlation between the level of Tregs and the level of WNV-specific
CD8+ T cells was found at day 8 after infection, with animals exhib-

Figure 4
Symptomatic WNV+ donors exhibit lower frequencies of Tregs. Evolution of Treg frequencies in 18 asymptomatic (AS) and 14 symptomatic
(S) WNV+ donors at 5 time points after index donation. The average
Treg frequency in the 17 WNV– donors at a single time point is represented by the dotted line. A minimum of 50,000 events were collected
in the lymphocyte gate. Error bars represent SEM.
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Figure 5
Age does not confound the relationship between Treg frequency and
symptomatic WNV infection. (A) Subject age within the 18 asymptomatic,
14 symptomatic donors; horizontal
bars represent mean age. (B) Treg
frequencies vs. age of 30 WNV +
donors at 30 days after index donation. Correlation coefficient = 0.187.

iting lower WNV-specific CD8+ T cell responses having higher Treg
levels (P = 0.012; Figure 6H), suggesting a possible protective effect
of Tregs through dampening of WNV-specific immune responses.
Although the WNV infection in mice recapitulates many features of
human disease (4), the frequency of severe infection and kinetics of
viral dissemination differ between the 2 models, likely accounting
for some of the observed disparity in Treg dynamics.
Increased lethality following WNV infection in mice lacking Foxp3+ Tregs.
To confirm the effect of Tregs on WNV infection and disease, we took
advantage of Foxp3DTR knockin mice; in these animals Tregs express
a diphtheria toxin receptor (DTR) on their cell surface. Treatment
of Foxp3DTR mice with diphtheria toxin specifically and completely
depletes the CD4+CD25+Foxp3+ cells (40, 41). Foxp3DTR mice that
were treated with DT at day –1 and day 0 relative to infection with
WNV showed more frequent and severe symptoms and weight loss
(P < 0.01 and P = 0.02, respectively; Figure 7A), resulting in significantly higher mortality rates (93%) compared with DT-treated or
untreated WT mice or untreated Foxp3DTR mice that were infected
with WNV (50%, 46%, and 44% mortality, respectively, P = 0.026; Figure 7B). Thus, an absence of Tregs at the earliest stage of WNV infection is detrimental to disease outcome in the mouse model.
Adaptive and innate immune mediators in WNV+ donors. One possible explanation for the increased Treg frequency in asymptomatic compared with symptomatic human subjects was that these
were driven by higher-magnitude effector T cell responses and/or
higher proinflammatory cytokines. To address this, IFN-γ production from PBMCs stimulated with 18 amino acid peptides overlapping by 11 residues spanning the entire WNV proteome was
quantified by ELISPOT (15). Notably, there was no significant difference between asymptomatic and symptomatic donors in terms
of the median number of WNV peptides recognized (asymptomatic = 1, symptomatic = 1.5 peptides, P = 0.3) or the magnitude of
response (asymptomatic = 75, symptomatic = 120 spot-forming
cells [SFCs]/106 PBMCs, P = 0.2), though the proportion of donors
making no detectable T cell response to WNV trended higher in
the asymptomatic group (P = 0.06; Figure 8, A and B). As previously demonstrated (42), most WNV+ donors seroconverted by
20 days after index donation, with a rapid and transient IgM
response and sustained IgG levels (Figure 8C). Again, no significant differences were observed in the kinetics or magnitude of
WNV-specific IgM or IgG responses (P = 0.6 for IgM and P = 0.7
for IgG) between symptomatic and asymptomatic individuals.
Tregs have complex interactions with cytokine networks that
regulate their generation, expansion, and suppressor activity.
Functionally important Treg-related cytokines include IL-2 (34),

IL-10 (43), IL-6 (44), and TGF-β (45). To determine whether differences in Treg levels correlated with differences in systemic cytokine
profiles, 11 asymptomatic and 8 symptomatic WNV+ donors
(selected based only on specimen availability) were screened for
cytokine and chemokine signatures at 5 different time points after
index donation, but no significant differences in plasma cytokines
or chemokines between asymptomatic and symptomatic WNVinfected donors were observed (Figure 8D).
Discussion
We describe, for what we believe is the first time, a longitudinal
study of Treg frequencies in WNV infection, made possible by
screening a large population of healthy blood donors for viral RNA
in plasma. Use of questionnaires allowed stratification of the study
population into symptomatic and asymptomatic groups. Tregs
were defined as CD3+CD4+CD25hiCD152+CD127– and shown to
express Foxp3 and suppress proliferation. Somewhat surprisingly,
Treg levels nearly doubled in the 3 months after infection in spite
of only a transient viremia in the study subjects, though potential
reservoir sites such as the spleen (39) and kidney (46) were not tested for viral persistence. The major finding of this study was that,
compared with asymptomatic donors, those with symptomatic
infection had lower Treg frequencies throughout WNV infection
and this difference persisted even 1 year after index donation when
Treg levels had fallen to a presumed baseline level. To our knowledge, this study shows the strongest correlation of Treg levels with
infectious disease outcome in humans reported to date (47).
Risk factors associated with severe WNV infection in humans
have been described, including older age, preexisting conditions
such as diabetes or hypertension (48), and genetic predisposition,
with the same deletion of the CCR5 gene that protects from HIV
infection being associated with severe WNV infection (49). Interestingly, the present study revealed lower Treg frequencies in symptomatic WNV+ donors even after the contraction phase 1 year after
index donation. If the Treg frequency 1 year after index donation
is used as a surrogate for the preinfection Treg baseline level, the
asymptomatic subjects may have had a higher “Treg tone” prior
to infection, with higher preinfection Treg frequencies associated
with protection from symptomatic disease. Alternatively, asymptomatic and symptomatic populations may have had similar Treg
frequencies prior to infection, but in the first 2 weeks of infection
(prior to the first Treg measurement) those with asymptomatic
infection had a more robust early Treg expansion.
As a preinfection sample was not available in our donor population, we utilized a well-characterized mouse model of WNV
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Figure 6
Lower frequency of Tregs in symptomatic WNV-infected mice. (A)
Percentage change in body weight for 8 hunched mice versus 12 nonhunched mice 8 days after infection; horizontal bars represent mean.
(B) Correlation between the percentage change in body weight and
the amount of WNV in the brain from 20 mice at day 8 after infection.
Correlation coefficient = 0.65. Plaque assay results for viral burden
in spinal cord (C) or brain (D) tissues collected from 12 asymptomatic and 8 symptomatic mice from a group of 20 mice sacrificed at
day 8 after infection; horizontal bars represent mean. (E) Percentage
survival for 40 mice over 28 days after infection. (F) Treg-gating strategy in mouse experiments. PBMCs were stained ex vivo for surface
TCRβ, CD4, CD25, and intracellular CD152 and Foxp3. Lymphocytes
were gated and dead cells excluded if positive for the Aqua-amine
dye. CD152+Foxp3+ Tregs were enumerated among CD4+TCRβ+ cells.
(G) Treg frequencies in mice that survived to day 28 after infection
(n = 17) and died prior to day 28 after infection (n = 18) are shown
before infection and at 14 days after infection. Error bars represent
SEM. (H) Association between high Treg frequencies and low WNVspecific CD8+ T cells in WT mice (n = 15) at 8 days after infection with
1 PFU of WNV. Horizontal bars represent means. Samples were classified as “high” WNV-specific CD8+ T cells if the value was higher than
the mean value for all the samples (3.1% of splenic T cells at day 8)
and “low” if the value was lower than the mean. **P < 0.01.

infection that in many respects resembles the human disease.
Unlike in humans, Treg levels did not increase in mice that survived WNV infection and actually fell in mice that died. Although
further study is warranted, one possible explanation for this difference is that mice are more susceptible than humans to WNV

and experience symptoms quickly after infection, dying around
day 10 to day 14 after infection. Humans are less susceptible to
WNV, and symptoms, if they develop, seem to persist for a longer duration, suggesting a slower viral clearance or protracted
inflammation. In support of the human data, we observed lower
Treg frequencies in symptomatic animals, though this difference
did not attain statistical significance at the preinfection time
point. Experiments with Foxp3DTR mice (50) showed an accelerated fatal infection with WNV after Treg ablation, establishing
a protective role of Tregs in WNV acute infection. As an inverse
correlation between the level of Tregs and the level of WNV-specific CD8+ T cells was observed in mice, we speculate that Tregs
may exert a protective effect by dampening the WNV-specific
immune response and inflammation.
While the current study was built on a unique set of donor specimens, some limitations were inherent in its design. Symptom questionnaires only covered the week before and 2 weeks after index
donation, limiting study of long-term effects of WNV infection.
Additionally, analysis of peripheral blood may not fully reflect
the situation at sites of infection, and lower peripheral Treg levels
may not correlate with tissue levels (39, 46, 47). Furthermore, this
study was drawn from a population of healthy donors who did
not develop severe, neurological disease. Finally, the correlation
between Tregs and disease outcome may not be sustained in subjects with neuroinvasive WNV infection, since high Treg levels, in
theory, could impair viral clearance from infected neurons. Against
this, however, experiments in mice indicate a net protective role for
Tregs during WNV infection.

Figure 7
Increased lethality following WNV infection in mice lacking Foxp3+ Tregs. (A) Fifteen untreated WNV-infected WT C57BL/6 mice (WT no DT), 15
DT-treated WNV-infected WT mice (WT + DT), 11 untreated WNV-infected Foxp3DTR mice (Foxp3-DTR no DT), and 14 DT-treated WNV-infected
Foxp3DTR mice (Foxp3-DTR + DT) were monitored for clinical scores and weight loss daily. DT treatment was given on day –1 and day 0. The
designation for the clinical scores is as follows: 1, ruffled fur/hunched; 2, paresis/difficulty walking; 3, paralysis; 4, moribund; and 5, dead. After
day 12, only 1 Foxp3-DTR (+DT) mouse survived. Error bars represent SEM. (B) The survival data are compiled from 4 independent experiments. P value for WT vs. Foxp3-DTR (+DT) = 0.0086; Bonferroni corrected = 0.026.
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Figure 8
Similar systemic effector immune responses in symptomatic and
asymptomatic human WNV infection. WNV-specific T cell responses
during the first 60 days after index donation. Comprehensive analysis of WNV-specific T cell responses by anti–IFN-γ ELISPOT assay
revealed (A) the median peak number of recognized WNV peptides
and (B) the median peak magnitude of responses over 3 time points
in the first 60 days after index donation for 18 asymptomatic and 14
symptomatic WNV+ donors. Horizontal bars represent median quantities. (C) IgM and IgG response over the 90 days after index donation
in 18 asymptomatic and 14 symptomatic WNV+ donors; means with
SEM bars are displayed. (D) Cytokine profiles after index donation.
Results are shown for analysis of plasma from 11 asymptomatic and
8 symptomatic WNV+ donors spanning the year after index donation.
Medians with SEM bars are displayed.

The behavior of natural Tregs in humans has been described
primarily for tuberculosis and chronic viral infections (51–53).
In HCV infection, another Flaviviridae family member, an inverse
correlation between Treg number in the periphery of liver biopsies and the histological inflammatory score was reported (54).
People chronically infected with HCV have more circulating Tregs
in peripheral blood than uninfected people or those who resolve
HCV infection (55). Interestingly, a decrease in Treg number
or function was found in the peripheral blood of symptomatic
patients infected with HIV (56) or HCV (57), but Treg levels in
acute HCV infection do not predict the ability to clear viremia
(58). Tregs have also been studied in dengue virus infection (a
Flavivirus that causes acute but not chronic infection), in which
Treg expansion but not the absolute level of Tregs was lower in
children with severe disease (47). While numerous studies have
shown Treg changes in disease states, none have correlated disease
outcome with a difference in Treg frequency.
We also explored potential factors that would differentially
affect Treg frequencies in the asymptomatic and symptomatic
donors. Previous studies reported higher frequencies of Tregs in
elderly subjects (37), but age did not correlate with symptomatic
status or Treg level in our study cohort. We also examined the
general level of immune activation in asymptomatic and symptomatic donors. Asymptomatic donors with higher Treg levels
did not possess significantly lower magnitude WNV-specific T
cell responses, although there was a trend to more asymptomatic donors having undetectable effector T cell responses, whereas
mice with higher Treg levels had a lower number of WNV-specific CD8+ T cells. Finally, no difference between asymptomatic
and symptomatic WNV+ donors was found in their antibody
responses or in the accumulation of selected systemic chemokines and cytokines in serum. Future studies will be required to
determine the contribution of innate immunity and the mechanisms of induction and action of Tregs, specifically, how they
ameliorate clinical outcome after WNV infection. In summary,
levels of Tregs appear to predict WNV disease outcome, with
higher Treg frequencies in the early phases of infection protecting from symptomatic infection. Although a CD8 + T cell
response is required to clear WNV infection (36), an excessive
response may cause immunopathology (13). Thus, the downregulation of an effective response by Tregs may be critical for
mitigating bystander injury and disease pathology in the CNS.
A better understanding of the dynamics, distribution, and function of Tregs may provide new avenues for pharmacologic control of viral pathogenesis.

Methods
Study design and subjects. From over 800,000 United Blood Services donations screened for WNV in 2005, 45 were confirmed positive for WNV
RNA at index donation and reactive on a follow-up sample for anti-WNV
IgM antibodies. Of the 35 WNV + donors willing to participate after
informed consent under UCSF Institutional Review Board approval,
symptom questionnaires were successfully completed for the 32 subjects
included in the current study. Samples were collected at regional blood
centers and shipped via courier to the Blood Systems Research Institute.
First PBMC samples were received a mean of 15 days after index donation, with follow-up samples extending to 1 year. Questionnaires covering 12 possible WNV-related symptoms (fever, headache, eye pain, body
aches, new skin rash, swollen lymph nodes, nausea or vomiting, muscle
weakness, confusion, disorientation, memory problems, or other) were
administered at study enrollment and 2 weeks after enrollment. Samples were also drawn from 17 age-matched healthy uninfected negative
control subjects (mean age = 42.2 years for WNV–; 47.4 years for WNV+;
P = 0.12). All WNV+ blood donors enrolled in this study tested negative
for other blood-borne pathogens, including HIV, HCV, HBV, human T
cell lymphotropic virus (HTLV), and syphilis.
WNV RNA and antibody detection. WNV RNA was detected using a Transcription-Mediated Amplification assay (Gen-Probe). Plasma specimens
were tested for WNV IgM and IgG using ELISA kits (Focus Diagnostics).
An IgG sample-to-calibrator ratio (SCR) of greater than 1.5 and an IgM
SCR of greater than 1.1 were considered positive. Time windows of 10 days
were selected for assessment of WNV antibody persistence. Multiple results
available for a given donor within a given time window were averaged.
Virus. The lineage I WNV strain (3000.0259) isolated in New York in
2000 (WNV-NY) was propagated once in C6/36 Aedes albopictus cells and
used for in vivo experiments. For survival comparisons between WT and
Foxp3DTR C57BL/6 mice, the WNV strain TX 2002-HC was used as previously described (5).
Animal experiments. Mice were bred under pathogen-free conditions.
Eight- to twelve-week-old WT of congenic Foxp3DTR C57BL/6 mice were
inoculated subcutaneously with WNV via the footpad. Diphtheria toxin
was administered intraperitoneally (50 μg/kg) at day –1 and (30 μg/kg) at
day 0. Mice were genotyped and bred in the animal facilities of the Washington University School of Medicine, and experiments were performed
with approval of the Washington University Animal Studies Committee.
Isolation of PBMC and T cell subpopulations: human samples. Plasma was collected after centrifugation, and PBMCs were isolated on a Ficoll-Paque
PLUS density gradient (GE Healthcare Life Sciences). Aliquots of 10 × 106
cells were frozen in medium containing 90% FBS (HyClone) and 10% DMSO
(Fisher BioReagents) and stored in liquid nitrogen. CD4+CD25+ cells were
positively isolated with magnetic beads using a human CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec). The average purity of the
CD4+CD25+ fraction was 86% (3 independent experiments) after a negative-selection enrichment step for CD4+ T cells followed by a second-step
positive selection for CD25+ cells and negative selection for CD25– cells.
Isolation of PBMC and T cell subpopulations: mouse samples. Blood was collected preinfection and on day 8, 14, or 28 after infection. PBMCs were
isolated by Percoll gradient centrifugation, washed, and frozen in RPMI
1640, 40% FBS, and 10% DMSO prior to characterization.
RT-PCR. mRNA was isolated from CD4+CD25+ or CD4+CD25– T cell subsets using an RNeasy Mini Kit (QIAGEN). Analysis of Foxp3 gene expression
by RT-PCR was performed using a QIAGEN OneStep RT-PCR Kit. Primers
used for RT-PCR were as follows: β-actin, forward: 5′-AGCCTCGCCTTTGCCGA-3′ and reverse: 5′-CTGGTGCCTGGGGCG-3′; Foxp3, forward:
5′-CACTGGGGTCTTCTCCCTC-3′ and reverse: 5′-TGTGCAGACTCAGGTTGTGG-3′ (Operon Biotechnologies Inc.).
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Flow cytometry: human samples. PBMCs were incubated with ethidium
monoazide for live cell gating. Stains included anti-CD14–TriColor, antiCD16–PECy5, anti-CD19–PECy5, anti-CD4–Alexa Fluor 700, anti-CD127–
PE, and anti-CD25–PECy7 (surface); anti-CD3–Pacific Blue, anti-CD152–
allophycocyanin (APC), and anti-Foxp3–FITC (intracellular).
Flow cytometry: mouse samples. PBMCs were stained with LIVE/DEAD
Aqua-amine (Invitrogen). Stains included anti-TCRβ–PECy5, anti-CD4–
Alexa Fluor 700, and anti-CD25–APC (surface); and anti-CD152–PE and
anti-Foxp3–PECy7 (intracellular).
Treg functional assays. CD4+CD25+ T cells (30 × 103) and the indicated ratio
of CD4+CD25– T cells labeled with 5 μM CFSE (Invitrogen) were cultured
for 4 days at 37°C and 5% CO2 in duplicate wells in 96-well round-bottom
plates (Corning Costar) with or without 2.5 μg/ml anti-CD3 and anti-CD28
(BD Biosciences). After 96 hours, cells were stained with propidium iodide,
anti-CD3–Pacific Blue, anti-CD4–Alexa Fluor 700, and anti-CD25–PECy7
(clone: MA-251) and were analyzed for CFSE dilution by flow cytometry.
WNV-specific CD8+ T cells. For detection of WNV-specific mouse CD8+ T
cells, splenocytes were restimulated ex vivo with a class I MHC Db-restricted
immunodominant NS4B WNV peptide (59) and incubated with FITC-conjugated anti-CD8 (BD Biosciences) at 4°C for 30 minutes. Subsequently,
cells were washed, fixed in 1% paraformaldehyde, permeabilized, and incubated additionally with Alexa Fluor 488–conjugated anti–IFN-γ prior to
analysis by flow cytometry.
ELISPOT assays. Peptides were divided into 93 pools of 8 to 10 peptides, with
each peptide present in 2 pools. The pattern of responses to the pools identified candidate peptides, which were retested individually in duplicate. PBMCs
were plated in 96-well MultiScreen-IP plates (Millipore) precoated with anti–
IFN-γ antibody (mAb1-D1K; Mabtech) at 2 μg/ml in PBS (UCSF Cell Culture
Facility). Cells were added at 100,000/well in 100 μl RPMI (UCSF Cell Culture
Facility) plus 10% human AB serum (Sigma-Aldrich), 11 mM glucose, 2 mM
l-glutamine, 23 mM NaHCO3P, and 50 U penicillin-streptomycin (termed
R10H). The final concentration of each peptide was 5 μg/ml. Duplicate negative control wells (cells plus medium) and a positive control well, 0.5 μg/ml
phytohemagglutinin (PHA) (Sigma-Aldrich), were run on each plate. Plates
were incubated 20 hours at 37°C and 5% CO2, then washed and incubated at
25°C for 60 minutes with biotinylated anti–IFN-γ antibody (Mabtech). Plates
were washed and incubated with streptavidin-alkaline phosphatase (Mabtech)
for 60 minutes at 25°C. Plates were washed prior to addition of 5-bromo-4chloro-3-indolylphosphate and nitroblue tetrazolium substrates (Bio-Rad).
Spots were counted, and results were expressed as SFCs/106 PBMCs after
background subtraction. Responses in 5 WNV– healthy controls ranged from
1. Hayes, E.B., et al. 2005. Virology, pathology, and
clinical manifestations of West Nile virus disease.
Emerg. Infect. Dis. 11:1174–1179.
2. Centers for Disease Control. 2009. West Nile virus
activity — Human disease cases reported. 2005–
2009. http://www.cdc.gov/ncidod/dvbid/westnile/
surv&control.htm.
3. Busch, M.P., et al. 2006. West Nile virus infections
projected from blood donor screening data, United
States, 2003. Emerg. Infect. Dis. 12:395–402.
4. Samuel, M.A., and Diamond, M.S. 2006. Pathogenesis of West Nile Virus infection: a balance between
virulence, innate and adaptive immunity, and viral
evasion. J. Virol. 80:9349–9360.
5. Keller, B.C., et al. 2006. Resistance to alpha/beta
interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80:9424–9434.
6. Wang, T., et al. 2003. IFN-gamma-producing
gamma delta T cells help control murine West Nile
virus infection. J. Immunol. 171:2524–2531.
7. Mehlhop, E., et al. 2005. Complement activation
is required for induction of a protective antibody
response against West Nile virus infection. J. Virol.
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0 to 30 SFCs/106 PBMCs, with over 80% of wells showing no spots. Responses
were counted as positive if they were 3 times above background of the plate
and consisted of 50 or more SFCs/106 PBMCs.
Cytometric bead array analysis of plasma cytokines and chemokines. Plasma was
available for 19 of the 32 panels described above and was analyzed by human
Th1/Th2 cytokine, inflammation, and chemokine Cytometric Bead Array
(CBA) kits (BD Biosciences) according to the manufacturer’s protocols (60).
Residual plasma volume was insufficient for testing on the remaining 13
subjects. Results were analyzed using BD CBA Analysis Software.
Mouse viral burden measurements. After extensive perfusion with PBS,
organs were removed and homogenized; titers were determined by viral
plaque assay on BHK21-15 cells as described (39).
Statistics. For Gaussian distributed data, statistical significance was evaluated using a Student’s 2-tailed t test and, where appropriate, a 2-tailed,
unpaired Student’s t test. Differences were considered significant if the
P value was less than 0.05. For non-Gaussian distributed data (i.e., cytokine
and chemokine measurements, viral burden data), the nonparametric MannWhitney rank sum test for 2 independent populations was performed using
GraphPad Prism software (GraphPad Software). For comparison of survival curves, the log-rank (Mantel-Cox) test with Bonferroni’s correction for
multiple comparisons was performed using GraphPad Prism software. For
comparison of multiple longitudinal measurements (e.g., Treg frequencies),
the mean value at each time period was calculated using generalized estimating equation regression for panel data within groups of subjects defined by
whether they had symptomatic or asymptomatic WNV infection using Stata
9.0SE software (Stata Corp.). We used robust standard errors to account for
multiple observations (serial bleed samples) from these individuals.
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